Latest news

• Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

  The trial met its primary endpoint, with the PSMA-targeted radioligand therapy demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) after treatment with androgen-receptor

• Novartis bags CHMP recommendation for prostate cancer drug Pluvicto

  If approved by the European Commission, Pluvicto would be the first and only commercial radioligand therapy for people with advanced prostate cancer in Europe. ... We are committed to exploring the potential of radioligand therapy to address unmet needs

• FDA approves Novartis’ Pluvicto for prostate cancer

  The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients.

• Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

  Novartis has revealed new data from a phase 3 trial evaluating its targeted radioligand therapy (RLT) in late stage advanced prostate cancer at the 2021 American Society of Clinical Oncology (ASCO) ... This] data from the first phase 3 study of a

• Novartis bolsters radioligand therapy pipeline with new licence agreement

  We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. ... compared the radioligand therapy plus best standard of care (SoC) to SoC alone.